Stratos Wealth Partners’s Phathom Pharmaceuticals PHAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-100,000
Closed -$1.08M – 1790
2026
Q2
$1.08M Hold
100,000
– – 0.01% 810
2026
Q1
$1.11M Buy
100,000
+49,700
+99% +$628K 0.01% 754
2025
Q4
$834K Buy
+50,300
New +$718K 0.01% 836

Other funds holding PHAT

Stratos Wealth Partners's PHAT Position: Q3 2026 in Review

Stratos Wealth Partners sold out of Phathom Pharmaceuticals (PHAT) in Q3 2026, closing a stake of 100,000 shares — an estimated $1.08M sold.

Stratos Wealth Partners first reported a position in PHAT in Q4 2025 and held it in 3 quarters. The position peaked at $1.11M in Q1 2026. 112 funds tracked by Wall St. Rank hold PHAT as of Q3 2026.

  • Stratos Wealth Partners reported no remaining Phathom Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Stratos Wealth Partners sold 100,000 Phathom Pharmaceuticals shares in Q3 2026, an estimated $1.08M.
  • Stratos Wealth Partners first reported a position in Phathom Pharmaceuticals in Q4 2025 and held it in 3 quarters.
  • Stratos Wealth Partners's Phathom Pharmaceuticals position peaked at $1.11M in Q1 2026.
  • 112 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2026.

Based on Stratos Wealth Partners's 13F filing for Q3 2026, filed 13 Nov 2026.